Free Trial
→ Trump’s Sending THIS Crypto Higher on Purpose (From Crypto 101 Media) (Ad)

Theracryf Interim Earnings Report

GBX 0.93 +0.06 (+6.63%)
As of 01/21/2025 11:40 AM Eastern
Earnings History

Theracryf EPS Results

Actual EPS
-GBX 29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Theracryf Announcement Details

Quarter
Interim
Date
11/28/2024
Time
Before Market Opens

Conference Call Resources

Theracryf Earnings Headlines

Theracryf Plc (TCF.L)
January 19 at 12:59 AM | ca.finance.yahoo.com
Theracryf PLC Share Chat (TCF)
January 13, 2025 | lse.co.uk
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

View Theracryf Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles